شنبه 3 شهریور 1403
دوره 9، شماره 4 - ( 7-1402 )
جلد 9 شماره 4 صفحات 251-244 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Razazian N, Sahraian M, Eskandarieh S, Jafari N, Rezaei M, Fakhri N. Follow-up of Patients With Multiple Sclerosis After COVID-19 Vaccination With Sinopharm Vaccine. Caspian J Neurol Sci 2023; 9 (4) :244-251
URL: http://cjns.gums.ac.ir/article-1-666-fa.html
URL: http://cjns.gums.ac.ir/article-1-666-fa.html
Follow-up of Patients With Multiple Sclerosis After COVID-19 Vaccination With Sinopharm Vaccine. مجله علوم اعصاب کاسپین. 1402; 9 (4) :244-251
چکیده: (365 مشاهده)
Background: Vaccination against COVID-19 for people with multiple sclerosis (PWMS) has been
recommended, but long-term follow-up needs further research.
Objectives: To follow up PWMS 3 months after vaccination with the Sinopharm vaccine regarding
the relapse of MS and infection with COVID-19.
Materials & Methods: The participants in this prospective study were PWMS over 18 years
of age living in Kermanshah Province, Iran, who received two doses of the Sinopharm vaccine
between August and November 2021. The information on demographic and clinical characteristics
of PWMS, COVID-19 infection, and relapses of MS 3 months after vaccination, were collected. We
contacted the patients using the information registered in the MS registry system of Kermanshah
Province, and the study data were collected by phone call and using a researcher-made questionnaire.
Results: Overall, 197 MS patients with a Mean±SD age of 41.84±11.0 years, including 155(78.7%) females
and 42(21.3%) males were studied. There was no significant difference (P=1.000) in MS relapse frequency
between the time points of 3 months before the first dose (15[7.6%]) and 3 months after the second dose
(15[7.6%]). The frequency of infection with COVID-19 within 3 months after the second dose (26[13.2%])
was significantly (P=0.017) higher than that in the 3 months before the first dose (12[6.1%]). Within 3 months
after the second dose, most PWMS with MS relapse or COVID-19 infection used oral and anti-CD20 therapy.
Conclusion: During the 3 months after the second dose, the frequency of MS relapse was not
different, but the frequency of COVID-19 infection was higher.
recommended, but long-term follow-up needs further research.
Objectives: To follow up PWMS 3 months after vaccination with the Sinopharm vaccine regarding
the relapse of MS and infection with COVID-19.
Materials & Methods: The participants in this prospective study were PWMS over 18 years
of age living in Kermanshah Province, Iran, who received two doses of the Sinopharm vaccine
between August and November 2021. The information on demographic and clinical characteristics
of PWMS, COVID-19 infection, and relapses of MS 3 months after vaccination, were collected. We
contacted the patients using the information registered in the MS registry system of Kermanshah
Province, and the study data were collected by phone call and using a researcher-made questionnaire.
Results: Overall, 197 MS patients with a Mean±SD age of 41.84±11.0 years, including 155(78.7%) females
and 42(21.3%) males were studied. There was no significant difference (P=1.000) in MS relapse frequency
between the time points of 3 months before the first dose (15[7.6%]) and 3 months after the second dose
(15[7.6%]). The frequency of infection with COVID-19 within 3 months after the second dose (26[13.2%])
was significantly (P=0.017) higher than that in the 3 months before the first dose (12[6.1%]). Within 3 months
after the second dose, most PWMS with MS relapse or COVID-19 infection used oral and anti-CD20 therapy.
Conclusion: During the 3 months after the second dose, the frequency of MS relapse was not
different, but the frequency of COVID-19 infection was higher.
| بازنشر اطلاعات | |
 | این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
